HEMISPHERIAN AS
925333409ActiveDeveloping novel small molecule drugs targeting TET2 for aggressive cancers.
Preclinical Pharmaceutical Companyhemispherian.com
Yleiskatsaus
- 5
- Työntekijät
- 269t NOK
- Liikevaihto
- 2020
- Perustettu
Avainpäättäjät
Roger Stupp
Chair of the Clinical Advisory Board
Michael Lim
Member of the Clinical Advisory Board
Monika Hegi
Member of the Clinical Advisory Board
Einar O. Vik-Mo
Member of the Clinical Advisory Board
+2 lisää yhteystietoja Funnelfeedrissä
Kuvaus
Hemispherian is an innovative preclinical pharmaceutical company dedicated to redefining targeted cancer therapeutics. The core focus is developing a novel class of small molecule drugs that specifically target the TET2 enzyme. These compounds are designed as targeted therapies for particularly aggr...
One-carbon Therapeutics AB